Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 4, 2008, Pages 627-630

  McCann, D J ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; BUPRENORPHINE; METHAMPHETAMINE; MODAFINIL; NALOXONE; NALTREXONE; NICOTINE; NOCICEPTIN; NORBINALTORPHIMINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE DERIVATIVE; OPIOID RECEPTOR LIKE1 AGONIST; PLACEBO; UFP 101; UNCLASSIFIED DRUG;

ALCOHOLISM; ANXIETY DISORDER; CLINICAL TRIAL; COCAINE DEPENDENCE; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG ANTAGONISM; DRUG BINDING; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INHIBITION; HUMAN; METHAMPHETAMINE DEPENDENCE; MONOTHERAPY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; SHORT SURVEY;

BUPRENORPHINE; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; MENTAL DISORDERS; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 40949140647     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100503     Document Type: Short Survey

References (36)

1. Vocci, F.J., Acri, J. & Elkashef, A. Medication development for addictive disorders: the state of the science. Am. J. Psychiatry 162, 1432-1440 (2005).
2. Dackis, C.A., Kampman, K.M., Lynch, K.G., Pettinati, H.M. & O'Brien, C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30, 205-211 (2005).
3. De Witte, P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict. Behav. 29, 1325-1339 (2004).
4. Ballon, J.S. & Feifel, D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatry 67, 554-566 (2006).
5. Carroll, K.M. & Rounsaville, B.J. Contrast of treatment-seeking and untreated cocaine abusers. Arch. Gen. Psychiatry 49, 464-471 (1992).
6. Mello, N.K., Mendelson, J.H., Bree, M.P. & Lukas, S.E. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science 245, 859-862 (1989).
7. Kosten, T.R., Kleber, H.D. & Morgan, C. Treatment of cocaine abuse with buprenorphine. Biol. Psychiatry 26, 637-639 (1989).
8. Schottenfeld, R.S., Pakes, J., Ziedonis, D. & Kosten, T.R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry 34, 66-74 (1993).
9. Montoya, I.D. et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin. Pharmacol. Ther. 75, 34-48 (2004).
10. Bodkin, J.A., Zornberg, G.L., Lukas, S.E. & Cole, J.O. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 15, 49-57 (1995).
11. Gerra, G., Fantoma, A. & Zaimovic, A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J. Psychopharmacol. 20, 806-814 (2006).
12. Rothman, R.B. et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J. Subst. Abuse Treat. 18, 277-281 (2000).
13. McLaughlin, J.P., Marton-Popovici M. & Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J. Neurosci. 23, 5674-5683 (2003).
14. Beardsley, P.M., Howard, J.L., Shelton, K.L. & Carroll, F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl.) 183, 118-126 (2005).
15. Toll, L. et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 178, 440-466 (1998).
16. Wnendt, S., Kruger, T., Janocha, E., Hildebrandt, D. & Englberger, W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol. Pharmacol. 56, 334-338 (1999).
17. Meng, F. et al. Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J. Biol. Chem. 271, 32016-32020 (1996).
18. Kotlinska, J., Wichmann, J., Legowska, A., Rolka, K. & Silberring, J. Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference. Behav. Pharmacol. 13, 229-235 (2002).
19. Lutfy, K., Khaliq, I., Carroll, F.I. & Maidment, N.T. Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats. Psychopharmacology (Berl.) 164, 168-176 (2002).
20. Mello, N.K., Lukas, S.E., Mendelson, J.H. & Drieze, J. Naltrexone-buprenorphine interactions: effects on cocaine self-administration. Neuropsychopharmacology 9, 211-224 (1993).
21. Gorelick, D.A. Regarding "Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system". Biol. Psychiatry 62, 702 (2007).
22. Ciccocioppo, R., Economidou, D., Rimondini, R., Sommer, W., Massi, M. & Heilig, M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol. Psychiatry 61, 4-12 (2007).
23. Martin-Fardon, R., Ciccocioppo, R., Massi, M. & Weiss, F. Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats. Neuroreport 11, 1939-1943 (2000).
24. Kuzmin, A., Sandin, J., Terenius, L. & Ogren, S.O. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J. Pharmacol. Exp. Ther. 304, 310-318 (2003).
25. Ciccocioppo, R., Economidou, D., Fedeli, A. & Massi, M. The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol. Behav. 79, 121-128 (2003).
26. Ciccocioppo, R. et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl.) 172, 170-178 (2004).
27. Le, A.D., Poulos, C.X., Harding, S., Watchus, J., Juzytsch, W. & Shaham, Y. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21, 435-444 (1999).
28. Walker, B.M. & Koob, G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology (epub ahead of print) (2007).
29. Zhao, R.J., Woo, R.S., Jeong, M.S., Shin, B.S., Kim, D.G. & Kim, K.W. Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport 14, 2383-2385 (2003).
30. Marco, E.M., Llorente, R., Perez-Alvarez, L., Moreno, E., Guaza, C. & Viveros, M.P. The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behav. Brain Res. 163, 212-218 (2005).
31. Conway, K.P., Compton, W., Stinson, F.S. & Grant, B.F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 67, 247-257 (2006).
32. Nyhuis, P.W., Specka, M. & Gastpar, M. Does the antidepressive response to opiate treatment describe a subtype of depression? European Neuropsychopharmacology 16(suppl. 4), S309 (2006).
33. Varty, G.B. et al. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl.) 182, 132-143 (2005).
34. Knoll, A.T., Meloni, E.G., Thomas, J.B., Carroll, F.I. & Carlezon, W.A. Anxiolytic-like effects of {kappa}-opioid receptor antagonists in models of unlearned and learned fear in rats. J. Pharmacol. Exp. Ther. 323, 838-845 (2007).
35. Maremmani, I., Pacini, M. & Pani, P.P. Buprenorphine as a psychoactive drug. Ital. J. Psychopathol. 12, 332-341 (2006).
36. Bortolato, M. et al. Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats. Biol. Psychiatry 57, 1550-1558 (2005).